Harbin Pharmaceutical Group
Chinese pharmaceutical company producing OTC medicines
Last updated October 9, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Harbin Pharmaceutical Group is a Chinese pharmaceutical group based in Harbin, Heilongjiang. The group is associated with a broad healthcare portfolio that includes over-the-counter medicines, prescription medicines, traditional Chinese medicines, and health-related products. Its consumer-facing identity is particularly connected with the Chinese over-the-counter medicines market, where pharmaceutical brands compete through product availability, retail distribution, recognizable formulations, and confidence in manufacturing quality. The group operates in a healthcare environment that combines prescription and self-medication demand. OTC products are generally purchased directly by consumers through pharmacies, hospitals with retail dispensaries, supermarkets, and online channels, while prescription products are supplied through medical and institutional channels. This mix gives a large pharmaceutical group the opportunity to serve both everyday treatment needs and more specialized therapeutic categories, although the relevant products, subsidiaries, and brands may differ across the group’s portfolio. Harbin Pharmaceutical Group’s brand identity is closely tied to Harbin and to China’s established pharmaceutical manufacturing base. The name is used at group level rather than describing a single medicine or a single therapeutic line. As a result, the group should be distinguished from individual product brands sold under its corporate umbrella. Publicly available material supplied for this entry does not establish a complete chronology of the group’s founding, ownership structure, listing status, executive history, product launches, campaigns, or controversies. Those details should be verified against the company’s official disclosures, regulatory filings, and authoritative Chinese-language business references before being added. The group’s principal positioning can therefore be described conservatively as a broad Chinese pharmaceutical and healthcare supplier with a strong OTC association. Its portfolio categories include non-prescription medicines, prescription medicines, traditional Chinese medicines, and health products. The available reference material does not provide sufficient evidence to identify a definitive flagship product, a current group chair or chief executive, precise international operating markets, or audited financial indicators. This dossier consequently avoids attributing specific products, dates, financial figures, or corporate events that cannot be reliably sourced.
History
Harbin Pharmaceutical Group developed as a pharmaceutical enterprise associated with Harbin, China, and is presented in the available material as a diversified healthcare group rather than a single-product brand. Its business scope covers OTC medicines, prescription medicines, traditional Chinese medicines, and health products. This portfolio places the group across both consumer healthcare and institutionally supplied pharmaceutical markets. The group’s OTC orientation is important to its public brand profile. OTC medicines depend on broad distribution, consumer recognition, pharmacy access, compliant product communication, and consistent manufacturing. In China, these products are sold through a mixture of traditional pharmacies, hospital-linked channels, retail networks, and increasingly digital commerce. A group operating across OTC and prescription categories can use shared manufacturing, research, quality, logistics, and commercial capabilities, although the exact organization of those functions within Harbin Pharmaceutical Group is not established by the supplied reference material. The group’s corporate name also reflects its geographic origin and gives it a regional identity within China’s pharmaceutical industry. However, the available sources do not reliably document a complete founding narrative, specific predecessor entities, major reorganizations, ownership changes, or the dates on which particular brands and facilities entered the portfolio. Nor do they establish a sufficiently detailed account of international expansion. These matters require confirmation from official company histories, annual reports, exchange filings, or authoritative reference works. In its current documented profile, Harbin Pharmaceutical Group is best understood as an active Chinese pharmaceutical group whose principal public-facing categories include non-prescription medicines, prescription medicines, traditional Chinese medicines, and health products. No specific flagship offering, leadership succession, campaign history, scandal record, or major strategic decision is included here because the supplied materials do not substantiate those details.
Listed on the Shanghai Stock Exchange under stock code 600664, becoming the first listed company in China's pharmaceutical industry and the first in Heilongjiang Province.
Harbin Pharma brand entered the China Top 500 Brands list.
Sponsorship signing for the 9th Asian Winter Games held at the Harbin Pharma No. 6 Factory print museum.
Penicillin sodium for injection passed generic drug consistency evaluation.
Harbin Pharma again placed on the 2023 China Top 100 Pharmaceutical Industry list.
Harbin Pharma Shiyitang Pharmaceutical Factory recognized as Heilongjiang industrial heritage.
Harbin Pharma released a new IP image.
A new Harbin Pharma product was approved for market.
Harbin Pharma selected for the first batch of Heilongjiang consumer brand enterprises; Shiyitang and Sanjing named as consumer brand growth enterprises.
Harbin Pharma won the 'West Lake Award' series at the 2025 Wuzhen Health Conference.
Products and positioning
A broad Chinese pharmaceutical and healthcare group with a notable association with over-the-counter medicines.
OTC medicines
Over-the-counter medicines
Consumer medicines intended for purchase and use without a prescription. The available material identifies OTC medicines as an important part of Harbin Pharmaceutical Group’s profile, but it does not provide a verified list of specific products, therapeutic categories, launch dates, or current brand status.
Prescription medicines
Prescription medicines
Medicines supplied through prescription and healthcare-provider channels. They form part of the group’s stated pharmaceutical scope, although the supplied references do not identify particular active ingredients, therapeutic franchises, indications, or product-level commercial information.
Traditional Chinese medicine
Traditional Chinese medicines
Traditional Chinese medicine products included among the group’s healthcare categories. No sufficiently sourced product list, formulation history, manufacturing site, or flagship offering is available in the supplied material.
Health products
Health products
Health-related consumer products associated with the group’s broader healthcare portfolio. The available material does not establish the precise subcategories, regulatory classifications, distribution channels, or individual brands represented in this area.
Controversies
2011
Pollution at Harbin Pharmaceutical's General Pharmaceutical Factory exposed and production ordered suspended for rectification
In 2011, Harbin Pharmaceutical Group's General Pharmaceutical Factory was exposed for waste gas and wastewater pollution problems, involving excessive levels of pollutants such as hydrogen sulfide; regulators ordered suspension of production for rectification. The company responded regarding environmental protection facilities and rectification arrangements; the subject of this entry is the involved general factory and related branch companies.
Sources5 sources
Cite this profile: Cite the canonical profile. /brand-wiki/哈药集团 · Editorial policy · How profiles are compiled